Abcam, ab235552, FPS-ZM1, RAGE receptor antagonist

Size: 5mg / 25mg
MW 327.8 Da, Purity >98%. High-affinity, blood-brain-barrier permeable, non-toxic, tertiary amide RAGE (Receptor for Advanced Glycation End products) receptor antagonist (K i = 25 nM). Blocks Aβ binding to the V domain of RAGE. Inhibits Aβ40- and Aβ42-induced cellular stress in RAGE-expressing cells in vitro and in the mouse brain in vivo .
Key facts
CAS number:945714-67-0,
Purity:>98%,
Form:SolidSee storage information,
Molecular weight:327.8 Da,
Molecular formula:C20H22ClNO,
PubChem:24752728,
Nature:Synthetic,
Solubility:Soluble in DMSO to 198.26 mMSoluble in ethanol to 198.26 mM,
Biochemical name:Fps-ZM1,
Biological description:High-affinity, blood-brain-barrier permeable, non-toxic, tertiary amide RAGE (Receptor for Advanced Glycation End products) receptor antagonist (Ki = 25 nM). Blocks Aβ binding to the V domain of RAGE. Inhibits Aβ40- and Aβ42-induced cellular stress in RAGE-expressing cells in vitro and in the mouse brain in vivo.,
Canonical smiles:C1CCC(CC1)N(CC2=CC=CC=C2)C(=O)C3=CC=C(C=C3)Cl,
InChi:InChI=1S/C20H22ClNO/c21-18-13-11-17(12-14-18)20(23)22(19-9-5-2-6-10-19)15-16-7-3-1-4-8-16/h1,3-4,7-8,11-14,19H,2,5-6,9-10,15H2,
InChiKey:XDFKWGIBQMHSOH-UHFFFAOYSA-N,
IUPAC Name:N-benzyl-4-chloro-N-cyclohexylbenzamide

Product details:
This product is manufactured by BioVision, an Abcam company and was previously called B1933 FPS-ZM1. B1933-5 is the same size as the 5 mg size of ab235552.

Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C, Storage information-Store in the dark, Store under desiccating conditions

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
RAGE also known as Receptor for Advanced Glycation End-products is a multi-ligand cell surface receptor with a molecular weight of approximately 45 kDa. It belongs to the immunoglobulin superfamily consisting of three extracellular immunoglobulin-like domains a transmembrane domain and a cytoplasmic tail. RAGE is widely expressed in various tissues throughout the body with high expression levels in the lungs heart and cells of the nervous system. The receptor can interact with several ligands such as advanced glycation end-products (AGEs) amyloid beta and S100/calgranulin proteins facilitating signal transduction into the cells.
Biological function summary
RAGE functions in the immune and inflammatory response where it mediates cell signaling that leads to cellular activation and the release of pro-inflammatory cytokines. It acts as part of complexes with different proteins contributing to cellular processes such as proliferation and migration. RAGE also plays roles in the regulation of oxidative stress and apoptosis impacting cellular health and survival. Researchers employ tools like 'anti-RAGE' antibodies and 'RAGER ELISA' assays to measure and study RAGE expression levels and its interactions in various experimental setups.
Pathways
RAGE is significantly involved in the NF-kB pathway and the MAPK signaling cascade. Its activation can lead to the release of NF-kB a transcription factor that plays an essential role in immune and inflammatory responses. RAGE interacts with proteins such as p38 MAPK leading to a cascade of events that regulate inflammation and stress responses. The signaling pathways involving RAGE are important in maintaining cell homeostasis and responding to cellular stressors and tools like 'anti-RAGE' and 'mouse RAGE' antibodies serve to elucidate these complex pathways further.
RAGE has strong associations with chronic diseases like diabetes and Alzheimer's disease. In diabetes RAGE binds to AGEs contributing to inflammation and vascular complications where it often interacts with proteins like iNOS and VEGF. In Alzheimer's disease RAGE is implicated in the accumulation and toxicity of amyloid-beta peptides interacting with proteins such as APP and tau. Understanding RAGE's role in these diseases can aid in developing therapeutic strategies employing reagents such as 'phen RAGE' and 'anti-RAGE' for targeted treatment approaches.